UGCG and B-cell chronic lymphocytic leukemia: Findings support that inhibiting UGCG either pharmacologically or genetically has a detrimental impact on leukemic cells, providing further support of the pro-oncogenic potential of UGCG and GluCer in the context of CLL (Fig. 8).